drugset / Trial / NCT06554639

A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)

NCT06554639

Phase 1 Completed 12 enrolled Merck Sharp & Dohme LLC
Non-randomizedSequentialOpen-labelTreatment

Summary

Researchers have designed a study medicine called MK-5684 as a new way to treat prostate cancer. The purpose of this study is to learn what happens to MK-5684 in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to MK-5684 in the body when it is given with and without another medicine called diltiazem.

Timeline

Start
2024-07-11
Primary completion
2024-08-05
Completion
2024-08-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Diltiazem Small molecule 240 mg Oral
Subject Opevesostat Small molecule Oral
Background Fludrocortisone Other / unclassified 0.05 mg Oral
Background Prednisone Other / unclassified 2.5 mg Oral
Background Prednisone Other / unclassified 5 mg Oral

Indications